StockData
Abivax S.A. logo

Abivax S.A. (ABVX) stock

ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 1/30
$82.10−1.51 (-1.81%)

Close on Nov 17, 2026Market cap $6.45BP/E –Yield –

Abivax operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Abivax's operating income for the twelve months ending Jun 30, 2026 was -€292.70M. For fiscal 2025 it was -€246.06M. The highest annual figure on record is -€41.40M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€246.06M–
FY2024Dec 31, 2024-€172.98M–
FY2023Dec 31, 2023-€127.38M–
FY2022Dec 31, 2022-€64.84M–
FY2021Dec 31, 2021-€41.40M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-€84.11M–
Q1 FY2026Mar 31, 2026-€56.23M–
Q4 FY2025Dec 31, 2025-€71.65M–
Q3 FY2025Sep 30, 2025-€80.71M–
Q2 FY2025Jun 30, 2025-€46.50M–
Q1 FY2025Mar 31, 2025-€47.20M–
Q4 FY2024Dec 31, 2024-€42.80M–
Q3 FY2024Sep 30, 2024-€50.19M–
Q2 FY2024Jun 30, 2024-€35.33M–
Q1 FY2024Mar 31, 2024-€44.67M–

More Abivax figures

See a number that looks wrong?